Tildrakizumab Every 12 Weeks Fits Shift Workers; Panel Weighs Scalp and Nail Data

A panel of dermatologists has walked through how scalp- and nail-specific efficacy data for tildrakizumab, secukinumab and ustekinumab should shape biologic selection in psoriasis patients with high-impact site involvement — and what monitoring should look like after the first injection.

The discussion, framed around a single clinical case in "Interpreting Scalp and Nail Efficacy Data for Psoriasis Biologics," centers on a patient whose busy, unpredictable shift schedule makes self-injection impractical. She and her dermatologist choose an HCP-administered biologic: tildrakizumab, an IL-23-targeted agent dosed every 12 weeks, the same therapy used in an earlier case in the series.

The 12-week interval matters for adherence. The patient schedules injections around her shifts, coordinating appointments before or after work, which meaningfully improves her ability to stay on therapy consistently, the panel notes.

What does the site-specific evidence show?

Dr. April Armstrong, asked by Dr. Christopher Bunick how she interprets scalp- and nail-specific efficacy data for tildrakizumab, secukinumab and ustekinumab in this patient, says site-specific data now exist for several biologics. That evidence helps her set realistic expectations with patients, even though head-to-head comparisons for these specific sites remain unavailable.

She describes the overall data as encouraging, showing meaningful improvement across these therapies. For patients with high-impact involvement, she prioritizes agents that are both highly effective and specifically studied in these difficult areas.

Dr. Bunick adds context on the evidence base: psoriasis and psoriatic arthritis are fortunate to have more head-to-head trial data than many other inflammatory dermatologic conditions. That advantage, however, has not yet extended to dedicated scalp-to-scalp or nail-to-nail comparisons between agents.

How should clinicians monitor after starting therapy?

Armstrong lays out a concrete follow-up routine for patients on a biologic:

• Evaluate high-impact site involvement at each follow-up visit.
• Ask about injection difficulties and recent hospitalizations.- Pay particular attention to tolerability issues — device problems or injection-site reactions — during the first year of therapy.
• Longer term, watch for waning efficacy.

She also flags non-medical switching between biosimilars as a potential confounder. When patients report new side effects, a recent payer-driven switch may explain the change rather than the disease or the drug itself.

What about breakthrough symptoms before the next dose?

For patients flaring before their next scheduled injection, Armstrong prefers requesting a shortened dosing interval through the payer over increasing the per-dose amount. She acknowledges payer approval is often difficult to secure, sometimes requiring peer-to-peer review.

When approval stalls, she turns to adjunctive topical therapy for stubborn plaques in the interim — a practical bridge that keeps patients on their regimen while the interval question works through utilization management.

What comes next in the series?

The panel's next installment, "A Patient's Psoriasis Journey: From Topicals to Biologic Therapy," brings a patient voice into the room. Keki Mody joins the discussion to share his three-decade experience living with plaque psoriasis, from topical treatments through to biologic therapy.